Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Raises $512 Million in Hong Kong IPO

publication date: Oct 24, 2012
Shanghai Fosun Pharma priced its Hong Kong IPO at the bottom of the announced price range, giving the transaction a value of $512 million – it was expected to raise $600 million. The price is a 13% discount from the shares on the Shanghai exchange. The offering was over-subscribed by a factor of two, but many of the institutional investors put in their bids at the bottom of the range, keeping a lid of the price. If the underwriters’ overallotment is exercised, the IPO will raise an additional $76.7 million. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital